Citation:Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, et al 2007

From Cancer Guidelines Wiki

Citation


Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007 May 20;25(15):2086-92 Available from: http://www.ncbi.nlm.nih.gov/pubmed/17513814.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
What is the optimal second-line therapy in patients with extensive stage small cell lung cancer?Associate Professor Michael Michael MBBS(Hons), BSc(Hons), MD, FRACPcompleted
What is the optimal systemic therapy and duration to be used for the treatment of limited stage small cell lung cancer?Associate Professor Michael Michael MBBS(Hons), BSc(Hons), MD, FRACPcompleted

Compare quality appraisals for each clinical question

  • [[Clinical question:What is the optimal second line therapy in patients with extensive stage small cell lung cancer?|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal second line therapy in patients with extensive stage small cell lung cancer?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:What is the optimal systemic therapy and duration to be used for the treatment of limited stage small cell lung cancer?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal systemic therapy and duration to be used for the treatment of limited stage small cell lung cancer?</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. What is the optimal second-line therapy in patients with extensive stage small cell lung cancer?